Is edaravone harmful? (A placebo is not a control)

References

• Turnbull J. Why is ALS so difficult to treat? Can J Neurol Sci. 2014;41:144–55.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M. Edaravone ALS Study Group. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–7.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Lancet Neurol. 2017;18: 505–12.
   Google Scholar
• Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, et al. July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:471–4.
   PubMed Web of Science ®Google Scholar
• Pro-Act Database: https://nctu.partners.org/ProACT. Accessed February 20, 2018. “Data used in the preparation of this article were obtained from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Database. In 2011, Prize4Life, in collaboration with the Northeast ALS Consortium, and with funding from the ALS Therapy Alliance, formed the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Consortium. The data available in the PRO-ACT Database has been volunteered by PRO-ACT Consortium members.”
   Google Scholar
• Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414–25.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257:1713–7.
   PubMed Web of Science ®Google Scholar
• Thakore NJ, Lapin BR, Pioro EP. Pooled Resource Open-Access ALS Clinical Trials Consortium. Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort. Muscle Nerve. 2018;57:937–45.
   PubMed Web of Science ®Google Scholar
• Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al. TCH346 Study Group. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007;6:776–84.
   Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045–53.
   PubMed Web of Science ®Google Scholar
• FDA analysis of edaravone https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000TOC.cfm. Accessed February, March 2018.There are 2 points at least of potential interest: Statistical review-executive summary (p6): “Study 19 does not seem very persuasive on it’s own since many of the secondary analyses were not nominally significant although the study was small. Some alternative subjective interpretation (e.g., risk benefit considerations or orphan drug status) would seem necessary if one was to view this submission as sufficient for approval ?.”Summary Review (p16): “In Study 16, the group of patients that did not meet the criteria for less severe disease (of the post hoc analysis) fared numerically worse than placebo, and an exploratory study conducted by the applicant in patients with more advanced disease (Study 18) also showed numerically worse results for edaravone than for placebo. Although these results do not definitely establish that edaravone has deleterious effects in more advanced patients, they certainly raise concern that edaravone efficacy decreases as ALS gets more severe.”
   Google Scholar
• Kirkinezos IG, Hernandez D, Bradley WG, Moraes CT. Regular exercise is beneficial to a mouse model of amyotrophic lateral sclerosis. Ann Neurol. 2003;53:804–7.
   PubMed Web of Science ®Google Scholar
• Deforges S, Branchu J, Biondi O, Grondard C, Pariset C, Lécolle S, et al. Motoneuron survival is promoted by specific exercise in a mouse model of amyotrophic lateral sclerosis. J Physiol. 2009;587:3561–72.
   PubMed Web of Science ®Google Scholar
• Itkin M, Mondshein JI, Stavropoulos SW, Shlansky-Goldberg RD, Soulen MC, Trerotola SO. Peripherally Inserted Central Catheter Thrombosis – reverse tapered versus nontapered catheters: a randomized controlled study. J Vasc Interv Radiol. 2014;25:85–91.
   PubMed Web of Science ®Google Scholar
• Fallouh N, McGuirk HM, Flanders SA, Chopra V. Peripherally inserted central catheter-associated deep vein thrombosis: a narrative review. Am J Med. 2015;128:722–38.
   PubMed Web of Science ®Google Scholar
• Yukisawa S, Fujiwara Y, Yamamoto Y, Ueno T, Matsueda K, Kohno A, et al. Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients. BJR. 2010;83:850–3.
   PubMed Web of Science ®Google Scholar
• Morgan M, Thrash WJ, Blanton PL, Glaser JJ. Incidence and extent of venous sequelae with intravenous diazepam utilizing a standardized conscious sedation technique. Part II: effects of injection site. J Periodontol. 1983;54:680–4. The control arm of this trial is of interest. Even a single antecubital infusion of 5% dextrose in water lasting less than 1 hour led to transient (3-4 days) local pain and tenderness, felt to be phlebitis, in 2 of 24 subjects.
   PubMed Web of Science ®Google Scholar
• Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. A randomized controlled trial. Ann Intern Med. 1991;114:845–54.
   PubMed Web of Science ®Google Scholar
• Holder MR, Stutzman SE, Olson DM. Impact of ultrasound on short peripheral intravenous catheter placement on vein thrombosis risk. J Infus Nurs. 2017;40:176–82.
   PubMed Web of Science ®Google Scholar
• Tagalakis V, Kahn SR, Libman M, Blostein M. The epidemiology of peripheral vein infusion thrombophlebitis: a critical review. Am J Med. 2002;113:146–51.
   PubMed Web of Science ®Google Scholar
• Ricard JD, Salomon L, Boyer A, Thiery G, Meybeck A, Roy C, et al. Central or peripheral catheters for initial venous access of ICU patients: a randomized controlled trial. Crit Care Med. 2013;41:2108–15.
   PubMed Web of Science ®Google Scholar
• Leung A, Heal C, Banks J, Abraham B, Capati G, Pretorius C. The incidence of peripheral catheter-related thrombosis in surgical patients. Thrombosis. 2016;2016:1.
   Google Scholar
• Wilson TJ, Brown DL, Meurer WJ, Stetler WR Jr, Wilkinson DA, Fletcher JJ. Risk factors associated with peripherally inserted central venous catheter-related large vein thrombosis in neurological intensive care patients. Intensive Care Med. 2012;38:272–8.
   PubMed Web of Science ®Google Scholar
• Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M, et al. POST (Prospective Observational Superficial Thrombophlebitis) Study Group. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med. 2010;152:218–24.
   PubMed Web of Science ®Google Scholar
• Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82:203–5.
   PubMed Web of Science ®Google Scholar
• Mishina M, Komaba Y, Kobayashi S, Kominami S, Fukuchi T, Mizunari T, et al. Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism. Neurol Med Chir. 2008;48:292–7.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Setoyama K, Kawahara KI, Nagasato T, Terashi T, Ueda K, et al. Edaravone, a synthetic free radical scavenger, enhances alteplase-mediated thrombolysis. Oxid Med Cell Longev. 2017;2017:6873281.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Sato T, Sakamoto K, Ishii H, Yamamoto J. The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model. Thromb Res. 2015;135:1209–13.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Yamashita T, Yamanishi H, Yamamoto J. The effect of edaravone to leukocyte rolling and adhesion molecule expression in microvessels. Health. 2013;05:402–8.
   Google Scholar
• Hoppe JO, Goble FC. The intravenous toxicity of sodium bisulfite. J Pharmacol Exp Ther. 1951;101:101–6.
   PubMed Web of Science ®Google Scholar
• Lewis GB, Hecker JF. Infusion thrombophlebitis. Br J Anaesth. 1985;57:220–33.
   PubMed Web of Science ®Google Scholar